TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06058936

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises using virtual reality technology
Description: this is a one-dimensional therapy game using (Handle/ or Multiball) five games are available for the Pablo©Handle which are (Recycle, Firefighters, Shooting Cans, Balloon, and Applehunter) The session will be 3 min for each game about 15 min for each session 3 times per week for 8 week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises using virtual reality technology
Description: this is a one-dimensional therapy game using (Handle/ or Multiball) five games are available for the Pablo©Handle which are (Recycle, Firefighters, Shooting Cans, Balloon, and Applehunter) The session will be 3 min for each game about 15 min for each session 3 times per week for 8 week
Study: NCT06077136

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body vibration
Description: 3 sessions per week consisted of different types of exercises, all of which were performed while the child will be is under WBV using (Galileo® MED 25 TT, Germany; 2021 model) with the following parameters:~* WBV session duration: 10 minutes (rest periods can be incorporated (1-2 minutes maximum 3 times during the session)~* frequency: 12 Hz~* Amplitude: 2 (fixed)~* duration of each exercise: 2-3 minutes~* starting positions differ according to each exercise; upper limb weight-bearing and weight shift (from prone, prone on elbows, sitting, standing).~* upper limb active exercises using toys/ balls / wand. Involving throwing, catching, transfer between both hands (according to the abilities of each child).~* coordination exercises by asking the child to approximate the index finger of both hands together, perform finger-to-nose (eyes open and closed), and finger-to-therapist finger exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard physical therapy
Description: all children will receive regular exercises according to their developmental abilities such as stretching, strengthening, facilitation, or inhibition as well as functional exercises. exercise sessions will be 3 times per week fo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard physical therapy
Description: all children will receive regular exercises according to their developmental abilities such as stretching, strengthening, facilitation, or inhibition as well as functional exercises. exercise sessions will be 3 times per week fo
Study: NCT05437900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure Microcatheter guided strategy - PIOS MC
Description: Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Wire guided strategy - PIOS - PW
Description: Use of Pressure Wire during PCI. After the PCI, the patient will receive treatment according to the incremental optimization strategy (PIOS) .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure Microcatheter guided strategy - Standard of care
Description: Use of Pressure Microcatheter during PCI. After the PCI, the patient will receive standard of care treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Wire guided strategy - Standard of care
Description: Use of Pressure Wire during PCI. After the PCI, the patient will receive standard of care treatment.
Study: NCT04385264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Day 0: 800mg PO OD (4 capsules) Days 1-5: 400mg PO OD (2 capsules daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mannitol
Description: Day 0: 4 capsules PO OD Days 1-5: 2 capsules daily PO OD
Study: NCT04773782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avapritinib
Description: oral administration
Study: NCT06110897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Dose Resistance Exercise Training
Description: Progressive resistance exercise training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Resistance Exercise Training Group
Description: Progressive resistance exercise training
Study: NCT04843449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC40
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC40
Description: Oral tablets
Study: NCT05931939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileal Interposition
Description: Bariatric surgery by laparoscopic Ileal Interposition

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional surgical technique
Description: Bariatric surgery by laparoscopic traditional technique
Study: NCT05156489

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Laser (Pixel CO2-Alma)
Description: The Laser will be administered at baseline (visit 2, day 0), at visit 3 (day 28±4) and at visit 4 (day 56±4) into vestibule, following the IFU of the device.
Study: NCT05505903

Intervention type: DIAGNOSTIC_TEST
Intervention: Temerature measurement
Description: Temerature measurement on admission to WBN or NICU

Intervention type: DIAGNOSTIC_TEST
Intervention: Temerature measurement
Description: Temerature measurement on admission to WBN or NICU

Intervention type: DIAGNOSTIC_TEST
Intervention: Temerature measurement
Description: Temerature measurement on admission to WBN or NICU
Study: NCT04843449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: Oral capsules
Study: NCT05948774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT200605 for Injection
Description: Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MT200605 Placebo
Description: Two stages (SAD, MAD) were designed in this study. For SAD, the MT200605 Placebo will single Intravenous (IV) infusion for 1h with the dose level as 0.15 mg/kg、0.3 mg/kg、0.6 mg/kg、0.9 mg/kg、1.2 mg/kg. For MAD, the participants will IV infusion of the MT200605 Placebo for 7 days with 2 times per day under the dose level of 0.3 mg/kg、0.6 mg/kg、1.2 mg/kg. The dosing frequency will be Q12h. The drug/placebo in day 7 will be only administrated for 1 time on morning. The infusion duration will be 1h.
Study: NCT04929600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: Sacubitril/valsartan oral tablets (200mg) one pill a day + matching placebo of amlodipine one pill a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine oral tablets (5mg) one pill a day + matching placebo of sacubitril/valsartan one pill a day.
Study: NCT05078775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEAAR Medical Food
Description: Standardized non-essential amino acid restricted medical food.
Study: NCT05121142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be given by mouth or enteral tube (if applicable).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib will be given by mouth or enteral tube (if applicable).
Study: NCT05099419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS uses pulses of magnetic energy to non-invasively stimulate the brain. The rTMS device to be used in this study is the Magstim Rapid2 Plus1. The rTMS device is connected to an active figure-of-eight coil which rests against the scalp and delivers the magnetic energy to the brain. The rTMS protocol is specified by the parameters of pulse frequency, duration of continuous pulse delivery, intensity, and stimulation location.~Each participant will receive two different standard rTMS protocols that have been used in past research studies for modulation of pelvic floor tone delivered over the motor cortex in an area that is known to control pelvic floor muscles.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS uses pulses of magnetic energy to non-invasively stimulate the brain. The rTMS device to be used in this study is the Magstim Rapid2 Plus1. The rTMS device is connected to an active figure-of-eight coil which rests against the scalp and delivers the magnetic energy to the brain. The rTMS protocol is specified by the parameters of pulse frequency, duration of continuous pulse delivery, intensity, and stimulation location.~Each participant will receive two different standard rTMS protocols that have been used in past research studies for modulation of pelvic floor tone delivered over the motor cortex in an area that is known to control pelvic floor muscles.
Study: NCT05951972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional
Description: participants will receive 2 pairs of food items to consume - pair A - Bananas and Apples, pair B - cucumbers and peanuts.
Study: NCT06511908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
Description: Arm 1 and 2 Experimental Intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
Description: Arm 1 and 2 Experimental Intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Arm 1 and 2 Control Intervention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Arm 1 and 2 Control Intervention
Study: NCT05131074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collabree Mobile Phone Application Medication Adherence Booster
Description: Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collabree Mobile Phone Application Medication Adherence Booster (simplified version)
Description: Patients take part in a 90-day program to promote medication adherence and a 90-day follow-up through the Collabree application. Patients will receive more information as to the exact functions and use of the mobile phone application when the application is installed on their mobile phone.
Study: NCT05966168

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Micra AV Device
Description: Participants will already be planned to have a Micra AV 2.0 device implanted. Participants will then undergo treadmill exercise testing and wear a Holter monitor to determine the effectiveness of the Micra AV 2.0 device during exercise or elevated heart rates.
Study: NCT04579692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial treatment
Description: Patients' head will be placed in ExAblate device to hold it still for the treatment. The ExAblate Transcranial helmet will be placed on their head. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area. This area is gradually heated while monitoring the patient's responses and neurologic examination.
Study: NCT04700618

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: The study group and the control group were vaccinated with one dose of vaccine and blood was collected after 28-40 days.
Study: NCT05755685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal treatment of recombinant modified human tumor necrosis factor (rmhTNF)
Description: 5 million IUrmhTNF, dissolved in 30-50ml normal saline, was intraperitoneal heat perfusion into the surgical focus after the operation;
Study: NCT04769544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with medial pivot tibial insert or symmetrical insert
Description: standard surgical implantation of total knee arthroplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: total knee arthroplasty with medial pivot tibial insert or symmetrical insert
Description: standard surgical implantation of total knee arthroplasty
Study: NCT05205421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus Injection(RT-01)
Description: Intravenous injection a single dose of RT-01
Study: NCT06337331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: 400mg/day PO Days -8 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m2/day IV Days -7 to -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/day IV Days -7 to -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2mg/kg/day IV Days -5 to -4

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: 200cGy Day -2
Study: NCT04977583

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmet Need Screening
Description: Participants are screened by phone for unmet social needs (e.g., utility insecurity, social isolation), hereafter referred to as the index screen. The index screen occurs prior to randomization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmet Need Screening
Description: Participants are screened by phone for unmet social needs (e.g., utility insecurity, social isolation), hereafter referred to as the index screen. The index screen occurs prior to randomization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmet Need Screening
Description: Participants are screened by phone for unmet social needs (e.g., utility insecurity, social isolation), hereafter referred to as the index screen. The index screen occurs prior to randomization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmet Need Referral - Resource Sheet
Description: Participants receive a Resource Sheet(s) tailored to the unmet need(s) identified in the index screen. For each unmet need, a Resource Sheet will include the names of available resource within the VA and/or the local community that can help address the unmet need and contact information (address, phone, website, email) and hours of operation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmet Need Referral - Resource Sheet
Description: Participants receive a Resource Sheet(s) tailored to the unmet need(s) identified in the index screen. For each unmet need, a Resource Sheet will include the names of available resource within the VA and/or the local community that can help address the unmet need and contact information (address, phone, website, email) and hours of operation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unmet Need Referral Assistance
Description: Participants receive assistance from a Social Worker (SW) to facilitate connection to resources that can help to address unmet need(s) identified in the index screen. Assistance includes 1) conducting a standardized bio-psychosocial assessment; 2) motivational interviewing methods to uncover details of the Veteran's unmet needs and identify barriers to resolving the unmet needs, and; 3) developing an action plan for the Veteran to connect with resources and address needs. The SW will conduct initial follow-up by phone one week after the interview/action plan development, with planned subsequent phone outreach every two weeks for up to seven weeks.
Study: NCT05253170

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Description: Radiation regimen of 2.5-3.0Gy x 13-17 fractions +/- sequential boost 0-7 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionation
Description: Radiation regimen of 1.8-2.0Gy x 23-28 fractions +/- sequential boost 0-5 fractions
Study: NCT05937191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Leflunomide+Glucocorticoids treatment Group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid Drug
Description: Steroid Treatment
Study: NCT05595356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Session description: An electric current of 2mA will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. The anode will be placed over the left dorsolateral prefrontal cortex and the cathode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: Session description: Three ramps of 30 seconds of current will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.~Session duration: 20 minutes~Frequency of sessions: Daily sessions, from monday to friday, skipping weekends, during 6 weeks.~Number of sessions: 30 sessions~The first randomized session will be delivered in the third assessment visit, two weeks after the run-in sham session.
Study: NCT04854031

Intervention type: DEVICE
Intervention: Cochlear Implants
Description: Individuals with cochlear implants will be tested on their hearing ability. Auditory recordings of speech will be played to participants from a loudspeaker. Recordings will be edited to add competing noise sources and to adjust talker voice pitch. Synthetic sounds will be manipulated to control auditory cue salience in detection tasks.
Study: NCT05595356

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: run-in sham transcranial direct current stimulation
Description: In the second assessment visit, one run-in 20-minute session of sham stimulation, consisting of three ramps of 30 seconds of current, will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: run-in sham transcranial direct current stimulation
Description: In the second assessment visit, one run-in 20-minute session of sham stimulation, consisting of three ramps of 30 seconds of current, will be delivered through 35 square centimeters electrodes covered by sponges dampened with saline to reduce impedance. One electrode will be placed over the left dorsolateral prefrontal cortex and the other electrode will be placed over the right dorsolateral prefrontal cortex. The electrodes will be fixed in a neoprene cap to ascertain their positioning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation video
Description: Watching a video, produced by the research team, containing a brief explanation of what depression is and how it's treated.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychoeducation video
Description: Watching a video, produced by the research team, containing a brief explanation of what depression is and how it's treated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tutorial video
Description: Watching a video, produced by the research team, containing instructions on how to operate de tDCS devices.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Tutorial video
Description: Watching a video, produced by the research team, containing instructions on how to operate de tDCS devices.
Study: NCT06214104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressur
Description: Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.The fetal position will be given with the newborn in the right side position, with the arms and legs joined in the midline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressur
Description: Acupressure Massage; It will be applied to BL 60 and K3 areas. The application will be applied in successive pressures with the thumb on each point for an average of 45-60 seconds.The fetal position will be given with the newborn in the right side position, with the arms and legs joined in the midline.
Study: NCT06125353

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Patients of the Intervention group (melatonin group) received a personalized dietary plan based on the Mediterranean Diet, together with a booklet of lifestyle guidelines (nutritional and physical activity), all generated by a Clinical Decision Support System (CDSS). Moreover, participants in the Intervention group consumed one melatonin tablet per day, containing 1 mg of melatonin, together with water for a total of three months.
Study: NCT05752279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma-Lyte 148
Description: Plasma-Lyte® 148 intravenous fluid for resuscitation in patients with keto-acidosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 0.9% sodium chloride intravenous fluid for resuscitation in patients with keto-acidosis